Karyopharm Therapeutics Inc (KPTI)


Stock Price Forecast

March 15, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Karyopharm Therapeutics Inc chart...

About the Company

karyopharm therapeutics inc. is a clinical-stage pharmaceutical company focused on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. for more information, please visit www.karyopharm.com

CEO

Michael Kauffman

Exchange

NASDAQ

Website

https://karyopharm.com/

$64M

Total Revenue

506

Employees

$174M

Market Capitalization

-1.18

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $KPTI News

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

17d ago, source: Insider Monkey

Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29.

KPTI Apr 2024 1.500 put

3d ago, source: Yahoo Finance

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate in ...

Karyopharm Therapeutics Inc. Q4 Loss misses estimates

18d ago, source: Business Insider

(RTTNews) - Karyopharm Therapeutics Inc. (KPTI) reported Loss for fourth quarter that missed the Street estimates. The company's bottom line came in at -$41.837 million, or -$0.36 per share.

Karyopharm Therapeutics Stock (NASDAQ:KPTI), Quotes and News Summary

25d ago, source: Benzinga.com

Karyopharm's Selinexor Shows Progression-Free Survival of 27.4 Months In Endometrial Cancer With Certain Mutation Karyopharm Therapeutics Inc (NASDAQ: KPTI) announced the presentation of updated ...

Karyopharm Therapeutics: Q4 Earnings Snapshot

18d ago, source: The Washington Post

NEWTON, Mass. — NEWTON, Mass. — Karyopharm Therapeutics Inc. (KPTI) on Thursday reported a loss of $41.8 million in its fourth quarter. On a per-share basis, the Newton, Massachusetts-based ...

Karyopharm Therapeutics Inc KPTI

12d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

18d ago, source: Stockhouse

NEWTON, Mass., Feb. 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results ...

Karyopharm Therapeutics Inc. (KPTI) Q4 2023 Earnings Call Transcript

18d ago, source: Seeking Alpha

At this time, I would like to welcome everyone to the Karyopharm Therapeutics Fourth Quarter and Full Year 2023 Financial Results Conference Call. There will be a question and answer session to ...

Karyopharm Therapeutics Inc

4d ago, source: U.S. News & World Report

What Is a Registered Investment Advisor? RIAs aren't just for the wealthy anymore, and they have a fiduciary duty to put their clients' interests first.

Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

18d ago, source: WKRN-TV

NEWTON, Mass., Feb. 29, 2024 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial ...

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2023 Earnings Call Transcript

18d ago, source: Yahoo Finance

Karyopharm Therapeutics Inc. misses on earnings expectations. Reported EPS is $-0.36 EPS, expectations were $-0.29. FDS isn't one of the 30 most popular stocks among hedge funds at the end of the ...

Karyopharm Therapeutics Inc.

19d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...